Halberd Corporation Adds Blood-Borne Disease Treatment Capability With Addition Of Noted Nephrologist

JACKSON CENTER, PA / ACCESSWIRE / August 11, 2021 / Halberd Corporation (OTC PINK:HALB) today confirmed the addition of Dr. Ned Kronfol as a member of its Scientific Advisory Board. Dr. Kronfol is certified by the American Board of Internal Medicine and retired in 2019 as Adjunct Clinical Professor from the William Carey University College of Osteopathic Medicine. Among many other notable accomplishments, Dr. Kronfol served as Medical Director- Renal Care Group/Fresenius Kidney Cat Lake Village, AR from 1987-2017.

Dr. Kronfol stated, "I look forward to contributing my knowledge of extracorporeal blood treatment to the exciting work and notable accomplishments at Halberd Corporation. Their technology has wide ranging applicability to various health afflictions, and I am happy to be a part of this groundbreaking work."

Dr. Mitchell S. Felder, Chief Technology Officer of Halberd Corporation stated, "The addition of the very distinguished Nephrologist, Dr. Ned Kronfol, will greatly expedite our work on extracorporeally treating blood-borne diseases, such as septicemia, which is responsible for the deaths of thousands of patients in intensive care units each year in America at a cost of tens of billions of dollars. In addition, the potential ability to physically remove very specific target antigens from the blood in a precise manner could lead to major breakthroughs against cancer, muscular dystrophy and even aging."

William A. Hartman, Chairman, President & CEO added, "Halberd Corporation has carefully chosen a strategic area in which to compete: 1) a high-demand, high-visibility health area; 2) where there is virtually no effective treatment or cure currently available; 3) where Big Pharma has either tried and failed or is otherwise not currently competing; 4) a field where we have solid patent protection; and 5) where once we have established proof-of-concept via laboratory and initial animal tests, interested individuals, larger organizations, and/or Big Pharma are almost compelled economically to participate with us.

"We believe that we have chosen wisely in our experimentations at ASU, GreenBioAZ, and Youngstown State University (YSU) to establish proof-of-concept of the eradication of disease antigens via our patented and extensive patent-pending extracorporeal methods involving lasers, radio frequency (RF), and our most recent, simplified Chemical Bonding Process^TM. After initial tune-up experimentations, we are currently conducting tests on E. Coli and Alzheimer's Disease (AD)/PTSD (Post Traumatic Stress Disorder)/CTE (Chronic Traumatic Encephalopathy) building blocks and cytokines involving cerebral spinal fluid (CSF). Although this level of testing with CSF has been successful thus far, we plan to continue this phase of experimentations for a relatively short period of time necessary to achieve all of our near-term, proof-of-concept objectives."

Hartman continued, "However, our strategic plan for the next program phase is to move to experimentations involving blood-borne diseases. Due to the added complexity of dealing with blood versus CSF, we decided that we need the best Nephrologist available, and we believe Dr. Kronfol is that person. He will begin immediately, and we look forward to adding his critical skills to our already robust organization. Once we employ our patented extracorporeal methodology with plasmapheresis, as appropriately directed by Dr. Kronfol, FDA applications will be initiated."

To get the latest news on Halberd's exciting developments, including our ongoing disease eradication accomplishments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/)

For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com ;
support@halberdcorporation.com
http://www.halberdcorporation.com
Twitter:@HalberdC

About Halberd Corporation.
Halberd Corporation (OTC PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. It holds the exclusive worldwide rights to several patent- and PCT-pending extracorporeal treatments for COVID-19 and other medical maladies: Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287.

Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). The Companies caution that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Companies undertake no obligation to revise these statements following the date of this news release.

Investor caution/added risk for investors in companies claiming involvement in COVID-19 initiatives -
On April 8, 2020, SEC Chairman Jay Clayton and William Hinman, the Director of the Division of Corporation Finance, issued a joint public statement on the importance of disclosure during the COVID-19 crisis.

The SEC and Self-Regulatory Organizations are targeting public companies that claim to have products, treatment or other strategies with regard to COVID-19.

The ultimate impact of the COVID-19 pandemic on the Company's operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak. Additionally, new information may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time.

We further caution investors that our primary focus and goal is to battle this pandemic for the good of the world. As such, it is possible that we may find it necessary to make disclosures which are consistent with that goal, but which may be adverse to the pecuniary interests of the Company and of its shareholders.

SOURCE: Halberd Corporation